×
About 798 results

ALLMedicine™ Agammaglobulinemia Center

Research & Reviews  264 results

Human adenoviral (HAdV) chronic arthritis expands the infectious spectrum of primary ag...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623974
Virology Journal; de Frémont GM, Salmona M et. al.

Nov 2nd, 2022 - Inborn errors of immunity (IEI) are a heterogeneous entity with an increasing number of late diagnoses. Besides infections, inflammatory manifestations are a growing part of the clinical landscape of IEI. These complications are of unknown causes ...

Immunogenicity and Safety of the Spikevax® (Moderna) mRNA SARS-CoV-2 Vaccine in Patient...
https://doi.org/10.1159/000526375
International Archives of Allergy and Immunology; Kralickova P, Jankovicova K et. al.

Oct 7th, 2022 - Reports on the immunogenicity and efficacy of the Spikevax® vaccine against SARS-CoV-2 in immunodeficient patients are still scarce. We aimed to evaluate the safety and immunogenicity of the vaccine in patients with primary humoral immunodeficienc...

Meningoencephalitis in primary antibody deficiency: Our experience from northwest India.
https://doi.org/10.1016/j.jneuroim.2022.577952
Journal of Neuroimmunology; Jindal AK, Chaudhary H et. al.

Aug 29th, 2022 - Patients with primary antibody deficiency (PAD) are predisposed to develop meningoencephalitis, often considered to be enteroviral. However, there is a paucity of literature on this subject, and there are no studies from developing countries. We a...

COVID-19-related health outcomes in people with primary immunodeficiency: A systematic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375253
Clinical Immunology (Orlando, Fla.); Drzymalla E, Green RF et. al.

Aug 17th, 2022 - A better understanding of COVID-19 in people with primary immunodeficiency (PI), rare inherited defects in the immune system, is important for protecting this population, especially as population-wide approaches to mitigation change. COVID-19 outc...

Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293955
Immunity Gao Y, Cai C et. al.

Aug 13th, 2022 - Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2 mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T cells post-mRNA vaccination in healthy individuals and patients with various fo...

see more →

Drugs  24 results see all →

Clinicaltrials.gov  6 results

COVID-19 Vaccine Responses in PIDD Subjects
https://clinicaltrials.gov/ct2/show/NCT05321407

Apr 11th, 2022 - Individuals with primary and secondary antibody immunodeficiency are at higher risk for severe COVID-19 disease. Humoral immunity is thought to be the predominant protection against COVID-19, however mRNA vaccines have been shown to elicit both an...

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)
https://clinicaltrials.gov/ct2/show/NCT00161993

Aug 24th, 2021 - The purpose of this study is to determine the pharmacokinetics, efficacy and safety of Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution in subjects with primary immunodeficiency (PID) manifesting as hypo- or agammaglo...

Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01441882

Apr 8th, 2021 - PRIMARY OBJECTIVES: I. To estimate the biologic target activity of dasatinib in CLL patients found to have pre-treatment in vitro dasatinib cytotoxicity (as defined by a >= 50% decrease in absolute lymphocyte count and/or bone marrow CLL count and...

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
https://clinicaltrials.gov/ct2/show/NCT02199496

Aug 24th, 2020 - The purpose of this study is to assess the safety/tolerability and efficacy of using ustekinumab in subjects with common variable immunodeficiency CVID or selective IgG subclass deficiency (functional agammaglobulinemia) who have associated sympto...

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
https://clinicaltrials.gov/ct2/show/NCT02960399

May 31st, 2018 - Common variable immune deficiency (CVID), specific antibody deficiency (SAD), and X-linked agammaglobulinemia (XLA) are among the most common primary antibody deficiencies in which the mainstay of treatment is gammaglobulin replacement. The use of...

see more →

News  20 results

Tisagenlecleucel Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma
https://www.onclive.com/view/tisagenlecleucel-approaches-eu-approval-for-relapsed-refractory-follicular-lymphoma

Apr 28th, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory follicular lymphoma following ...

Byrd Discusses Optimizing Ibrutinib and Idelalisib in CLL
https://www.onclive.com/view/byrd-discusses-optimizing-ibrutinib-and-idelalisib-in-cll

Dec 20th, 2020 - John C. Byrd, MD In a presentation at the inaugural ASH Meeting on Hematologic Malignancies, John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib (Imbruvica) and idelalisib (Zydelig) in chronic ...

Ibrutinib Represents "Transformative" Approach in CLL Treatment
https://www.onclive.com/view/ibrutinib-represents-transformative-approach-in-cll-treatment

Dec 5th, 2020 - Jennifer R. Brown, MD, PhD Jennifer R. Brown, MD, PhD, and John Byrd, MD, leading researchers in the emerging field of Bruton tyrosine kinase (BTK) inhibition in chronic lymphocytic leukemia (CLL) and other B-cell malignancies, discussed key ques...

BTK Inhibitor Success Puts Focus on Resistance Mechanisms
https://www.onclive.com/view/btk-inhibitor-success-puts-focus-on-resistance-mechanisms

Dec 5th, 2020 - Krithika Subramanian, PhD Less than 5 years after Bruton tyrosine kinase (BTK) inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged. The robust poten...

The Changing Treatment Landscape in MCL and CLL: A Review of Standards of Care
https://www.onclive.com/view/the-changing-treatment-landscape-in-mcl-and-cll-a-review-of-standards-of-care

Dec 5th, 2020 - Non-Hodgkin Lymphoma (NHL) is 1 of the 10 most common malignancies, accounting for approximately 3% to 4% of cancer cases worldwide.1 Over 30 different subtypes of NHL have been identified.2 Of these, B-cell lymphomas make up the majority of cases...

see more →

Patient Education  5 results see all →